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Tuberculosis is an ancient infectious disease that remains a threat for public health around the world. Although the etiological agent
as well as tuberculosis pathogenesis is well known, the molecular mechanisms underlying the host defense to the bacilli remain
elusive. In this paper we focus on the innate immunity of this disease reviewing well-established and consensual mechanisms like
Mycobacterium tuberculosis interference with phagosomematuration, less consensualmechanism like nitric oxide production, and
new mechanisms, such as mycobacteria translocation to the cytosol, autophagy, and apoptosis/necrosis proposed mainly during
the last decade.
1. Introduction
The history of tuberculosis (TB) mixtures with the history
of humanity since TB is one of the oldest infectious diseases
aﬀecting mankind. Bone TB was identified in 4000 years
old skeletons, from Europe and Middle East, as the cause
of death, showing that this disease was already a widespread
health problem back then. In recorded history, Hippocrates
writes about patients with wasting away associated with
chest pain and coughing, frequently with blood in sputum.
These symptoms allowed Hippocrates to diagnose TB, which
at that time was called “consumption”. The frequency of
descriptions of patients with these symptoms indicated that
the disease was already well entrenched in ancient times.
During the 16th and 17th centuries, the explosion of the
European population and the growth of large urban centres
made this continent the epicentre of many TB epidemics.
Although during the first half of the 19th century, the
incidence of TB peaked, causing death to approximately one
quarter of the European population, in the second half of this
century, TB mortality decreased due to improving sanitation
and housing. The 20th century brought a steadily drop of
morbidity and mortality due to TB, in the developed world,
due to better public health practices, massive vaccination
with Calmette-Gue´rin bacillus (BCG) vaccine and the advent
of antibiotics such as streptomycin. This downward trend
ended in the mid-1980s, triggered by emergence of acquired
immunodeficiency syndrome (AIDS) and an increase in
homelessness and poverty in the developed world. This fact
pointed to the important role played by the immune system
in this disease and also to the importance of socioeconomical
factors. More recently, we assisted to the identification of
multidrug resistant (MDR) strains, defined as mycobacteria
resistance to at least rifampicin and isoniazid (two first line
anti-TB drugs) and extensively drug resistant (XDR) strains,
defined as MDR mycobacteria with additional resistance to
fluoroquinolones and at least one of the injectable second
line antituberculosis drugs [1–3]. Notably, M/XDR-TB have
been recognized by the World Health Organization (WHO)
as the major challenge to be addressed in order to eradicate
tuberculosis [4].
Currently, more than one-third of the world’s population
is infected with Mycobacterium tuberculosis (M. tuberculosis).
According to the latest report released by the WHO, in 2009,
there were 9.4 million incident cases, 14 million prevalent
cases, 1.3 million deaths among HIV-negative people and
0.38 million deaths among HIV-positive people [3]. In
addition to these already frightening numbers, people who
are latently infected constitute the hidden reservoir of the
disease from which new cases of active disease can emerge
[3]. New eﬀective drugs, against either replicating or latent
bacilli, better vaccines, and new diagnostic methods are
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desperately needed to change and overcome this situation.
Despite the big eﬀorts made in order to develop new tools to
fight this plague, no good candidates have been found. The
first step towards this goal would be a better understanding
of the host-pathogen relationship. In this paper we will
focus on the progress that has been done on the study of
Mycobacterium-host interactions and its importance for the
understanding of tuberculosis pathogenesis as well as for the
discovery of new therapeutic targets.
2. The Etiological Agent
The Mycobacterium tuberculosis complex includes strains of
five species—M. tuberculosis, M. canettii, M. africanum, M.
microti, and M. bovis and two subspecies—M. caprae and
M. pinnipedii [5]. These mycobacteria are characterized by
99.9% similarity at nucleotide level and virtually identical
16S rRNA sequences [6–9] but diﬀer widely in terms of host
tropisms, phenotypes and pathogenicity [5, 10, 11].
The most notable member of the complex is M. tuber-
culosis the causative agent of human tuberculosis which
has an exclusive tropism for this host. In contrast M.
bovis, the etiologic agent of bovine tuberculosis, causes only
5%–10% of human tuberculosis cases with a pathobiology
indistinguishable from the one caused by M. tuberculosis and
a wider host spectrum. The impact of M. bovis in human
health declined sharply after the advent of pasteurization but
there are records of new cases among immunocompromised
individuals as well as re-activation cases amongst elderly
individuals [12]. The third member of the complex with an
important, although geographically circumscribed, impact
on human health is M. africanum which is responsible for
half of the TB cases in West Africa [13–15].
3. The Pathogenesis of Tuberculosis
Tuberculosis is an airborne disease, since the infectious
bacilli are inhaled as droplets from the atmosphere. In the
lung, the bacteria are phagocytosed by the alveolar macro-
phages. The interaction of mycobacteria components with
macrophage receptors, such as Toll-like receptors (TLRs)
results in the production of chemokines and cytokines
[16] that serve as infection signals. These signals result in
migration of monocyte derived macrophages and dendritic
cells from the blood stream to the site of infection in the
lung. The dendritic cells that engulf bacteria then mature
and migrate to the lymph nodes [17–19]. Once there, CD4
and CD8 T cells are primed against mycobacterial antigens.
Primed T cells expand and migrate back to the focus of
infection in the lungs, probably in response tomediators pro-
duced by infected cells. This phenomenon of cell migration
towards the infection focus culminates in the formation of
a granuloma, the hallmark of TB. The granuloma is formed
by T cells, macrophages, B cells, dendritic cells, endothelial
and epithelial cells, among others in a proportion that varies
with its age. This granuloma prevents the spreading of bacilli
resident within macrophages and generates an immune
microenvironment which facilitates the interaction between
cytokines secreted by macrophages and T cells. However,
the granuloma also provides housing for M. tuberculosis
during a long period of time. The latent bacilli can be later
released if the cytokine balance is broken, triggering disease
reactivation.
4. Mycobacteria Entry and the Triggering
of Signalling Cascades into Host Cells
The interaction of M. tuberculosis with host cells is complex
and far from being fully elucidated. The entry of M.
tuberculosis into macrophages seems to occur via cholesterol-
rich domains (rafts) of the plasma membrane [20], being
mediated by receptor binding and phagocytosis. Despite
the numerous in vitro studies that clearly identify diﬀerent
receptors involved in M. tuberculosis uptake, mainly by
macrophages and dendritic cells [21, 22], the results obtained
in vivo in receptor-deficient animals did not support the in
vitro data [21, 23]. In this scenario, it is almost consensual
that in vivo mycobacteria uptake is made by multiple
receptors, such as C-type lectin receptors, complement
receptors and scavenger receptors, rather than by a single
receptor-mediated pathway, implying the activation multiple
signalling cascades.
The majority of the in vitro studies indicate that the
bacilli favour interaction with complement and mannose
receptors, which are benign, because they trigger minimal
superoxide production. In contrast, mycobacteria uptake
by Fc receptors, which play a minor role in the absence
of specific antibodies [24], would trigger a vigorous host
response and would establish a distinct intracellular traﬃck-
ing pathway. This might explain why virulent mycobacteria
avoid internalization by these receptors [21, 25]. However,
the majority of experimental data suggest that the receptor
type has little impact on intracellular survival of the bacteria
[21, 22, 26].
The macrophage mannose receptors are expressed on
mature macrophages and allow uptake of virulent M. tuber-
culosis H37Rv but not of avirulent H37Ra. The interaction
between these receptors and mycobacteria seems to be
mediated by the terminal residues present in mycobacteria
lipoarabinomannam (LAM) [27, 28] that are also involved
in CD14 interaction. Since the expression of these receptors
is downregulated by gamma interferon (γ-IFN), their role
in mycobacteria ingestion is restricted mainly to early stages
of infection and to individuals with compromised cellular
immunity [29]. In addition to mannose and complement
receptors, other receptors such as surfactant protein A
receptors [30], class A [26] and B scavenger receptors [23]
and C-type lectin receptor (mincle) [31] are involved in
mycobacteria uptake associated with a low proinflammatory
response.
The Toll-like receptors (TLRs), which belong to the
group of pattern recognition receptors (PRRs), are likely
to be responsible for the immune recognition of pathogens
in macrophages and thus for the pro-inflammatory cell
signalling [32]. This class of receptors recognize pathogen
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associated-molecular patterns (PAMPs). In the case of myco-
bacteria, they recognize the main component of mycobac-
teria cell wall LAM [33] and trehalose 6,6′-dimycolate
(TDM/cord factor) [34]. Interestingly, pathogenic mycobac-
teria avoid binding to this family of receptors by preventing a
strong proinflammatory response at early stages of infection.
A large number of TLRs were identified in mammals
and two of them, TLR2 and TLR4, have been implicated
in the activation of macrophages by mycobacteria involving
MAP kinases (ERK 1/2, p38, and JNK), Janus kinase/signal
transducer and activator of transcription (JAK/STAT) and
NF-κB pathways [34, 35]. The activation of these host-
cell signalling cascades culminates with pro-inflammatory
cytokines (such as IL-1, TNF-α, and interferons) and
chemokine production. Pathogenic but not nonpathogenic
mycobacteria have evolved mechanisms to suppress these
signal transduction cascades and thereby attenuate the
cytokine-induced immune response [34, 35].
Extracellular signal-regulated kinases (ERK 1/2) and p38
are members of MAP kinase family and became activated
through the phosphorylation of tyrosine and threonine
residues. Pathogenic mycobacteria such as M. avium and
M. tuberculosis modulate MAP kinase activity. This leads
to a decrease in pro-inflammatory response exemplified by
a decrease in cytokine secretion such as TNF-α and their
downstream eﬀector and nitric oxide (NO). Since TNF-
α receptors are true death receptors, the decrease in the
production of this cytokine, induced by blockade of NF-κB
and MAP kinase activation, results in apoptosis inhibition.
This outcome is extremely important, since apoptosis is
believed to constitute an eﬀective mechanism of intracellular
mycobacteria killing [36] (discussed in more detail further in
this paper).
5. Mycobacteria Persistence and
Host Defence Mechanisms
Macrophages play a unique role in host response tomycobac-
terial infections. These cells represent both the primary
eﬀector cell for killing and the habitat in which mycobac-
teria reside. In order to survive pathogenic mycobacteria
developed strategies to evade detection by the host immune
system. Here, we discuss some of the most important
strategies adopted by pathogenic mycobacteria to persist
within macrophages.
5.1. NO and Reactive Nitrogen Radicals (RNI) Synthesis. The
first microbicidal activity that any intracellular microbe will
encounter within the macrophage is the oxidative burst
[37]. This is a nonspecific immune mechanism triggered by
microbes that results in the production of highly reactive
chemical species known as reactive nitrogen intermediates
(RNIs) and reactive oxygen intermediates (ROIs) [38].
Among ROIs, we found intermediate reaction products of
O2 en route to water, namely, superoxide, hydrogen peroxide
and hydroxyl radicals. In the case of RNIs the products
correspond to molecular species in diﬀerent oxidation
states ranging from nitric oxide to nitrate. Among them
is peroxynitrite, a powerful oxidant, originated from the
reaction of an RNI (nitric oxide) with an ROI (superoxide)
[38–40]. Mycobacterium tuberculosis has been shown to be
highly resistant to ROIs, such as hydrogen peroxide [41] or
hydroxyl radicals [42], and susceptible to RNIs such as nitric
oxide (NO) [43], so we will focus in this paper on the latter.
NO generated in macrophages by the inducible nitric
oxide synthase (iNOS: murine or by the human variant
NOS2) and its derivatives are produced in response to
bacterial infection. Pro-inflammatory cytokines (e.g., γ-IFN
and TNF-α) and bacterial lipopolysaccharides (LPS) enhance
NO synthesis [44–46]. The antimycobacterial eﬀects of these
intermediates were shown experimentally in macrophage
cultures infected with Mycobacterium [47, 48]. Other studies
in the murine model of infection involving iNOS inhibitors
or mice with disruption in the gene nos2 highlighted the
crucial role played by RNI in host defence against Mycobac-
terium infection [43, 49–52]. In contrast, the importance of
NO and RNI in human defence against M. tuberculosis is a
matter of controversy [53–56].
In conclusion, it seems that NO generated by iNOS
or NOS2 is required for mycobacteria killing. However,
it is unlikely that an eﬀective killing would be achieved
without delivery of bacteria to acidic compartments (late
endosome/lysosomes) as suggested by the studies of diﬀerent
laboratories [51, 55]. Indeed, analysis of γ-IFN activated
macrophages provided evidence that NO and RNI are insuf-
ficient to clear mycobacteria in the absence of acidification
[55]. At low pH, NO bactericidal eﬀects are boosted by
conversion of nitrite to nitrous acid and its subsequent
decomposition, culminating with the generation of NO [57,
58].
The in vitro tolerance of mycobacteria to RNI is strain,
dose and time dependent, with pathogens being inherently
more resistant than nonpathogens [58–61]. This suggests
that pathogenic mycobacteria express genes that counteract
the bactericidal or bacteriostatic eﬀects of RNI. Diﬀerent
experimental approaches led to the identification of noxR1
and noxR3 which are able to confer RNI, and also ROI,
resistance by a still unknown mechanism [62, 63]. Another
gene involved in protection from oxidative stress is ahpC
[64]. The product of ahpC, the alkyl hydroperoxide reductase
subunit C (AhpC), can metabolise peroxynitrite anion
into nitrite, thereby contributing to detoxifying this highly
reactive species [65]. Peroxynitrite is a powerful oxidant
produced by activated macrophages that can exert its toxic
eﬀects through protein modification [65, 66]. In vitro studies
have shown that M. tuberculosis is resistant to this oxidant
species but M. smegmatis and BCG are susceptible [67].
5.2. Phagosomal Maturation Arrest. Ingestion of invading
microorganisms by phagocytosis is an essential component
of the innate immune response. Phagocytosis is a multi-
step process consisting of receptor-mediated recognition of
particles which triggers signaling cascades responsible for
extensive actin cytoskeletal rearrangement and membrane
remodeling [68–70] culminating with particle engulfment.
After internalization, the resulting phagosome undergoes
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Figure 1: Maturation process of pathogen-containing phagosomes. Diagram outlining the diﬀerences between endosome progression to
lysosome (center), maturation of a phagosome harboring a live pathogen, for example, M. tuberculosis H37rv (left) and a phagosome
harboring a dead pathogen (right). The fusion processes of phagosomes containing live/dead pathogens with compartments of the
endosomal pathway are indicated by bold arrows. The traced arrows indicate inhibition of the fusion events between the phagosome
harboring the live pathogen and the endocytic compartment. The diagram also illustrates the importance of two components of the cell’s
cytoskeleton in phagosome maturation. Actin is recruited to the phagocytic cup and might nucleate on the phagosome membrane during
the maturation process. The microtubules, to which endocytic vesicles and phagosomes are thought to bind during the maturation process,
are also represented. EE: early endossome; MVB: multivesicular bodies; LE: late endosome; LY: lysosome. Diagram adapted from [71].
maturation. This process involves sequential interactions
with components of the endocytic pathway and culminates
in fusion with lysosomes and formation of a phagolysosome
[71]. The phagolysosome is an organelle with acidic pH,
high content of hydrolases and defensins with the ability to
generate toxic oxidative compounds, responsible for routine
elimination of microorganisms [72, 73]. However, some
microorganisms such as M. tuberculosis have developed the
ability to arrest phagosomal maturation, thereby averting
killing and causing infection [74].
Phagosome maturation follows a defined biochemical
program involving the sequential interaction with compo-
nents of the endocytic pathway (Figure 1). The phagosome
maturation involves both fusion and fission events that can
be described by the kiss and run model of phagosome
maturation [75]. A phagosome, which normally matures
into the phagolysosome, fuses initially with early endosomes
in an Rab5-dependent fashion and acquires the properties
of this endocytic organelle. Thus, an early phagosome is
characterized by the presence of Rab5 and its eﬀectors
such as the early endosome antigen 1 (EEA1), Class III
PI3K, and its product phosphatidylinositol 3 phosphate
[PI(3)P]. The transferrin receptor (TfR) is also present
in the phagosomal membranes at this early stage. This
organelle is also characterized by a relatively poor content
of proteases and a mildly acidic pH of around 6. Some
of these early markers are recycled from the phagosomal
membrane back to the plasma membrane (such as TfR) as
maturation proceeds [76, 77]. Thus, via fusion and fission
events, phagosomes acquire new molecules and recycle
others. Although the kinetics of maturation diﬀer greatly
and depend both on the particle phagocytosed and the
cell, phagosomes begin to fuse with late endosomes and
become refractory to early endosomes about 15–30 minutes
after formation [71, 77, 78]. The loss of Rab5 and Rab7
acquisition enables subsequent fusion of the phagosome
with older organelles, such as late endosomes and lysosomes
[75, 79]. As a consequence of phagosome aging, they lose
the early endocytic markers and become enriched in late
endosomemarkers, which are best exemplified by Rab7, lyso-
bisphosphatidic acid (LBPA), and the mannose-6-phosphate
receptor cation independent [78, 80]. Nevertheless, the
presence of these markers is also transient since the late
phagosome evolves into a phagolysosome characterized by
the presence of mature forms of lysosomal enzymes such
as cathepsin D, lysosome associated membrane protein 1
(LAMP 1) and a luminal acidic pH ranging between 4 and 4.5
[71].
However, the use of more advanced quantitative tech-
niques to evaluate the maturing phagosomal proteome
revealed that the classical model of three consecutive fusions
events with diﬀerent endosomal systems (described above)
is probably overly simplistic. Indeed, two quantitative prot-
eomic studies [81, 82] have demonstrated that there are likely
more distinct fusion events, presumably with subpopulations
of the three main classes of endosomes suggesting that
maturation is far more complex than a single Rab5 to
Rab7 transition. Therefore, several other Rab proteins among
other components of vesicular traﬃc such as SNARES,
tethering factors and motor proteins must be integrated into
thismodel to obtain amore completemap of the phagosomal
maturation.
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Intracellular pathogens have evolved highly specialised
mechanisms to enter and survive within their hosts, result-
ing in devastating diseases. In order to do this, bacterial
pathogens need to avoid host cell degradation and obtain
nutrients and biosynthetic precursors, as well as evade
detection by the host immune system [83–90]. The noto-
rious success of M. tuberculosis, a facultative intracellular
pathogen, rests upon the ability to arrest the biogenesis of
the phagolysosome. The ability of this pathogen to enter
host macrophages and persist in friendly phagosomes, which
do not mature into phagolysosomes [89, 91–93], is crucial
for tuberculosis infection, latency, disease activation, and
spreading and suppression of immunological detection by
the host [73, 74, 94, 95]. To create an intracellular niche that
is favourable for replication, Mycobacterium inhibits themat-
uration of the phagosome by modifying its identity through
the exploitation of host cell traﬃcking pathways. Indeed, fol-
lowing phagocytosis, the bacteria continue to reside within
a membrane-bound vacuole of host origin. The seminal
studies of D’Arcy Hart in the early 1970s described how the
absence of fusion correlated with viability of the infecting
bacteria [25, 91, 96]. The capacity of M. tuberculosis to
regulate the fusogenicity of phagosomes is shared with other
pathogenic mycobacteria such as M. avium and M. bovis.
In 1986, Frehel and colleagues observed transient delivery
of lysosomal tracers to phagosomes containing M. avium
and suggested that these phagosomes had access to early
endosomal compartment [97]. Moreover, in 1991 Crowle et
al. [98] reported that phagosomes containing M. avium and
M. tuberculosis were less acidic than neighbouring lysosomes.
Furthermore, Sturgill-Koszycki et al. [99] reported that the
pH ofmycobacteria-containing phagosomes was around 6.2-
6.3. Later on, it was shown that mycobacteria containing
phagosomes are dynamic compartments with a paucity of V-
ATPase complexes, which are responsible for the phagosomal
acidification, and a profile of endosomal constituents con-
sistent with the arrest of phagosome maturation at a point
that retained fusion with early endosomes [100]. Markers
of the recycling endosomal system, namely, the TfR, could
also be shown to traﬃc through the mycobacteria-containing
phagosome [100, 101]. Most researchers in this field are
now working under the assumption that the phagosome
containing pathogenic Mycobacterium is blocked at early
stages of the maturation process [43, 73, 74, 92, 102–104].
It is thought that the maturation block occurs between the
stages controlled by Rab5 and Rab7, being the latter excluded
from the M. tuberculosis phagosome [80, 105, 106]. Of note,
certain “lysosomal” markers, such as cathepsin D, could be
detected in this compartment but a careful analysis revealed
that it is an immature form of the enzyme [100, 107]. Thus,
the strategies M. tuberculosis has developed to survive, and
even replicate, inside the host is a subject of an intense
investigation.
Mycobacterium-containing phagosome acquires Rab5
which in its active or GTP-bound state is able to recruit
VPS34, a class III phosphatidylinositol 3-kinase responsible
for PI(3)P synthesis. A model of how M. tuberculosis
blocks phagosomematuration has emerged, based on altered
VPS34 recruitment tomycobacterial phagosomes and altered
PI(3)P patterns relative to the canonical model, latex bead
phagosomes [78, 108]. PI(3)P is essential for phagosome
maturation into a phagolysosome, and inhibition of PI(3)P
production arrests phagosome maturation [78, 109]. Failure
in PI(3)P synthesis by VPS34 can be attributed to the
interference with the kinase activity by a Ca2+/calmodulin
mediated process [110]. However, results published by
Corvera and collaborators suggest that calmodulin does
not aﬀect VPS34 kinase activity but rather blocks EEA1
binding to PI(3)P [111]. More recently, Deretic’s group
[112] has shown that in addition to the known eﬀects of
Mycobacterium on suppressing Ca2+ fluxes [113–115], it also
encodes a phosphatase that dephosphorylates PI(3)P and
inhibits phagosome-late endosome fusion. These findings
help to explain how live M. tuberculosis maintains the
phagosome maturation block and avoids lysosomal com-
partments. Despite the finding that M. tuberculosis interferes
with calmodulin and Ca2+-mediated signalling and the fact
that it encodes a PI(3)P phosphatase, the controversy about
the reasons behind the absence of PI(3)P in the phagosomal
membrane during M. tuberculosis infection still persists.
Although the majority of the studies on mycobacterial
pathogenesis have been focused on Rab5 and Rab7, two
GTPases that are known to play key roles in intracellular
traﬃc, it is expected that other Rabs are also involved [116,
117]. Rabs regulate intracellular traﬃcking and maintain
organelle identity by controlling incoming and outgoing
cargo through budding, transport, tethering, docking, and
fusion of vesicular intermediates, thus overseeing the vecto-
rial transport of proteins andmembranes between organelles
[116]. If we take into account that in eukaryotic cells,
organelle identity is determined, in part, by the composition
of active Rab GTPases on the membranes, the retention or
exclusion of Rab proteins from phagosomal membranes can
also explain, at least in part, their escape from the degradative
lysosomal pathways. Indeed, Rab10, Rab14, and Rab22 were
also identified as contributors to the arrest of mycobacte-
rial phagosomes by playing a role in the maintenance of
Mycobacterium phagosome in its immature early endosomal-
like stage [116, 118, 119]. Recently, it was also shown that
Rab10 overexpression changed the properties of the M. bovis
BCG-containing phagosomes. These authors reported that
phagosomal membranes harboring BCGwere acquired EEA-
1, a marker excluded from the phagosomes in control cells
(cells not transfected) [118].
5.3. Mycobacterium Translocation to the Cytosol. It is known
that several intracellular pathogens such as Listeria, Shigella,
Ricketsia, and Trypanossoma cruzi [83, 84] translocate to
the cytosol in order to avoid degradation within the
phagolysosome. This phenomenon was also described for
M. marinum, which causes tuberculosis-like disease in their
natural hosts, fish and frog [120] and “fish tank granuloma”,
a granulomatous skin syndrome, among humans [121].
In infected cells, M. marinum is able to escape from the
phagosome by a process not fully understood, in which
pore formation in the Mycobacterium containing vacuole
induced by the virulence factor early secreted antigenic
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target-6 (ESAT-6) might play an important role [122]. Once
in the cytosol, M. marinum induces actin tail formation and
initiates cell-to-cell spread. Although the mechanism of tail
formation induced by M. marinum is largely unknown, there
is evidence for the involvement of a nucleation promoter
factor known as Wiskott-Aldrich syndrome protein (WASP),
in a process dependent of the actin related proteins complex
2/3 (Arp 2/3) [123, 124]. More recently, another mechanism
of cell-to-cell spread mediated by an actin-based structure
called the ejectosome has been described for both M.
marinum and M. tuberculosis in Amoeba (Dictyostelium).
The specialized secretion system required for virulence (ESX-
1), also responsible for secretion of ESAT-6, is involved in
this process, which also encompasses coronin and Myosin
II instead of Arp2/3 complex [125]. Clearly, more studies
are needed to show whether the ejectosome and actin tail
formation are concurrent or concerted strategies adopted by
virulent mycobacteria to spread from one cell to another
[126].
The escape of M. tuberculosis to the cytosol has been
described by several groups [127–129] although none of
them described the formation of actin tails. In all studies,
the conclusions are based on the analysis of transmission
electron microscopy data. In the two earlier studies, plastic
embedding of the samples was performed [127, 128]. This
technique did not allow the use of immunogold techniques
for labeling with antibodies against the endocytic markers
described in the previous section, such as LAMP-1 and
EEA-1. However, despite the use of diﬀerent types of
macrophages both groups concluded that the nature of
mycobacteria-containing compartment changed over time.
Initially, mycobacteria were found in membrane enclosed
compartments and after 1 [128] or 4 days [127] a significant
number of M. tuberculosis H37rv was seen in the cytosol. In
both studies a diﬀerence was also noticed in the behavior of
mycobacteria with distinct virulence features. The virulent
strain M. tuberculosis H37rv, translocates more eﬃciently to
the cytosol than the attenuated strain M. tuberculosis H37ra
or the vaccinal strain M. bovis BCG. However, the ability
of Mycobacterium tuberculosis H37rv to translocate is lost
when the bacilli are heat killed prior to internalization by
macrophages. The explanation for these observations was
provided years later by Van der Wel and colleagues [129].
In their work, advanced EM techniques, such as Tokuyasu
cryo section and tomography were applied. These techniques
allow immunogold staining and 3D reconstitution of indi-
vidual mycobacteria, permitting more accurate conclusions.
An additional strength of this work is the use of macrophages
and dendritic cells derived from human monocytes, the
natural host of M. tuberculosis. The authors showed that 2
days after infection M. tuberculosis progressively translocates
from the phagolysosome to the cytosol and, once there,
it is able to replicate faster than in membrane-enclosed
compartments. This behaviour was not observed for BCG,
in agreement with the previous studies. The explanation to
this outcome is based in the genomic region of diﬀerence
1 (RD1), which is present in M. tuberculosis and M. leprae
but deleted in BCG [130]. This genomic region characteristic
of virulent mycobacteria encodes for virulence factors, such
as the ESAT-6, which isalso secreted by M. marinum that
translocates to the cytosol, and culture filtrate protein 10
(CFP-10).
5.4. Autophagy as an Immune Response to Mycobacterium
Infection. Autophagy sometimes referred as “the art of self-
eating” is a crucial process to cellular homeostasis and allows
the cell to ingest and digest portions of its own cytosol, assur-
ing an eﬃcient “housekeeping” service [131]. This cellular
process has three phases: initiation, elongation and closure,
and maturation and is characterized by the emergence of a
membranous organelle called the autophagosome (reviewed
in [132]). This organelle captures cytosol components, such
as defective organelles and large macromolecular aggregates,
and intracellular pathogens such as Toxoplasma gondii [133],
Streptococcus [134], Shigella [135], and Mycobacterium [136–
140], delivering them for lysosomal degradation by diﬀerent
processes including ubiquitin mediated degradation [139] in
autolysosomes.
For M. tuberculosis it has been shown that autophagy
induced pharmacologically or by starvation leads to
mycobacteria delivery to lysosomes and subsequent killing
[136]. Several key molecules for this process have been
identified, including murine Irgm1 (LRG-47) guanosine
triphosphate and its human orthologue IRGM, which is
important for controlling Mycobacterium infections [137,
140]. In addition, PI(3)P, a key lipid in diﬀerent cellular
processes such as phagosome maturation, has been shown
to be a central target for autophagy [141]. Although there is
no doubt concerning the relevance of autophagy in innate
and adaptive immunity in response to microbial infections,
including by mycobacteria [142–144], more studies need to
be performed in order to elucidate the molecular mecha-
nisms and machinery involved in this process.
5.5. Host Cell Death and Mycobacterium Persistence: Apoptosis
versus Necrosis. Recently, the induction of host macrophage
necrosis, a type of cell death that favours M. tuberculosis
survival within the host and is driven only by virulent
Mycobacterium has been proposed as a novel virulence
mechanism [145]. Cell necrosis is characterized by disrup-
tion of host surface membrane, facilitating escape of M.
tuberculosis into the surrounding tissue for a new cycle of
infection and dissemination from the lung to other tissues.
In contrast, macrophage apoptosis, which is the alternative
cell death modality, results in enhanced host defense by
killing of intracellular M. tuberculosis and by boosting the
adaptive immune response [146–149]. Indeed, macrophage
apoptosis has been suggested as a novel defense mechanism
against tuberculosis. Apoptosis of infected macrophages may
act as an antimicrobial innate defense mechanism, and
inhibition of apoptosis and induction of necrosis may serve
as microbial virulence mechanisms. Apoptosis sequesters the
pathogens within the cell, which facilitates eﬃcient pathogen
killing [150–152], promotes antigen presentation [153] and
enhances microbicidal activity bymacrophages and dendritic
cells, that engulf apoptotic corpses [150].
The crucial role played by apoptosis in mycobacteria
clearance was shown by the discovery of Irp1 gene [154].
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Mice lacking this gene are extremely susceptible to M. tuber-
culosis and their infected macrophages undergo necrosis. In
contrast, expression of Irp1 limits M. tuberculosis replication
and leads infected macrophages toward apoptosis. The
antimycobacterial mechanisms triggered by apoptosis are
complex and heterogeneous. In early studies, it was suggested
that the integrity of the genetic material of the bacilli
could be compromised [155] and the control of acidification
and fusion of Mycobacterium-containing phagosomes were
subverted during apoptosis, depriving the pathogen from its
intracellular niche [156]. More recently, it was proposed that
enhanced killing of mycobacteria in apoptotic macrophages
could be driven by stabilization of mitochondrial permeabil-
ity transition [150] or by an ATP/P2X7 purinergic receptor
apoptotic-mediatedmechanism not yet fully elucidated. This
process probably involves enhancement of Mycobacterium
containing phagosome fusion with lysosomes [157], in
accordance with previously reported observations [156, 158].
Another possible mechanism for P2X7 mediated mycobacte-
ria killing is the crosstalk between apoptosis and autophagy
[159].
Several mechanisms have been proposed to explain
apoptosis inhibition by M. tuberculosis. The interference with
TNF-α, a cytokine that plays a key role in mycobacteria
pathogenesis [95], was among the first mechanisms proposed
[160, 161]. It was suggested that M. tuberculosis evades
apoptosis of host macrophages by inducing the release of
soluble TNFR2 which complexes with TNF-α and decreases
its activity in an IL-10-dependent manner [162]. Another
hypothesis explored was the ability of pathogenic M. tubercu-
losis to alter the permeability of macrophage mitochondrial
membrane in such a way that favours necrosis instead
of apoptosis [145]. More recently, it was reported that
the mechanisms determining whether infected macrophages
undergo apoptosis or necrosis relay on two distinct lipid-
mediators of host signaling, PGE2 and LXA4. These lipid
mediators have a common precursor, arachidonic acid (AA).
AA is released from phospholipids present in the cytoplasmic
membrane by the cytosolic enzyme phospholipase A2 [163]
and its degradation by either 5-lipoxigenase or cycloxygenase
2 generates LXA4 or PGE2, respectively. Although lipids
such as eicosanoids play an important role in disease (for
review see [164]) and particularly in tuberculosis [165],
the mechanisms triggered by mycobacteria to control lipid
metabolism are far from being fully elucidated. Virulent
M. tuberculosis induces the production of LXA4, which
suppresses PGE2 synthesis and leads to macrophage necrosis.
In contrast, avirulent Mycobacterium induces only small
amounts of LXA4 production in infected macrophages.
Instead, these infected cells produce PGE2, which results
in cellular apoptosis rather than necrosis. Furthermore,
Alox5−/− mice, which are unable to synthesize LXA4, have
a greater ability to control virulent M. tuberculosis infection
compared to wild-type mice [146]. In addition, in trying to
elucidate a key downstream event modulated by these dis-
tinct modes of lipid-mediated signaling, plasma membrane
(PM) disruptions of infected macrophages induced by M.
tuberculosis infection were reported [148, 166]. Importantly,
whereas infection by avirulent forms of M. tuberculosis allows
the host to repair these PM defects, virulent infection blocks
this host repair process. As a result of this block, infected
macrophages undergo necrosis rather than apoptosis. Taking
clues from elucidated mechanisms of PM repair that occur
in other settings, such as traumatic disruption of the PM,
it was further defined that membrane transport from the
Golgi and lysosome contributes to host PM repair that occurs
during avirulent infection [144]. Moreover, these transport
pathways become blocked during virulent infection. Thus,
membrane repair seems to be a critical mechanism that
results in impermeability of the apoptotic macrophage lead-
ing to containment of M. tuberculosis and its products within
the phagosome. In conclusion, the ability of M. tuberculosis
to precisely modulate the outcome of a programmed cell
death process probably represents one of the important
immune-evasion strategies that make this organism such a
formidable challenge to global health.
6. Final Remarks
Despite the intensive work on the mycobacteria field and the
use of cutting-edge technology, such as EM techniques and
genome-wide screenings for mycobacteria and host, many
questions remain unanswered. This can be explained by
the Mycobacterium complexity and its ability to adapt to
the host environment. Indeed, M. tuberculosis has a variety
of important immune-evasion strategies representing one
of most challenging pathogen to mankind. Among these
strategies is the subversion of host membrane machinery
that is important for the uptake, survival, and replication of
this pathogen. In the future, the identification of all the host
machinery involved in phagocytosis and phagosomal mat-
uration will certainly help in understanding how Mycobac-
terium manipulates host membrane transport pathways,
providing mechanistic insights into how infection occurs
and revealing new information on biochemical processes
involved in the functioning of the host cells.
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